VEGF Signaling Pathway Knockout Cell Lines for Angiogenesis & Disease Research

Unlock Angiogenesis Research with Ready-to-Use VEGF Pathway KO Models

Overview of the VEGF Signaling Pathway

The VEGF (Vascular Endothelial Growth Factor) signaling pathway is a key regulator of angiogenesis, playing a critical role in both physiological and pathological conditions. It promotes the orderly formation of new blood vessels by regulating endothelial cell (EC) proliferation, migration, and survival.

The VEGF family consists of multiple ligands, among which VEGF-A is the most potent driver of angiogenesis.
l VEGF-A isoforms, generated through alternative splicing, exhibit distinct biological properties: VEGF-A165: the most abundant isoform with strong pro-angiogenic activity and heparin-binding capability VEGF-A121: highly diffusible but with relatively lower activity VEGF-A189: tightly binds to the extracellular matrix, forming localized concentration gradients
l VEGF-B and PlGF (Placental Growth Factor) primarily bind to VEGFR-1, contributing to metabolic regulation and pathological angiogenesis
l VEGF-C and VEGF-D are synthesized as precursors and activated through proteolytic processing (e.g., by furin, ADAMTS3, plasmin). They mainly regulate lymphangiogenesis but can also contribute to angiogenesis
l PlGF can form heterodimers with VEGF-A, enhancing signaling strength The differential expression and binding properties of these ligands define the spatial and temporal specificity of VEGF signaling, ensuring precise regulation of vascular growth, stability, and function.

Downstream Signaling Mechanisms

VEGF ligands activate transmembrane receptor tyrosine kinases—especially VEGFR-2 (KDR/Flk-1)—to initiate downstream signaling cascades:
· PI3K/AKT pathway: promotes endothelial cell survival, inhibits apoptosis, and enhances vascular stability via eNOS activation
· MAPK/ERK pathway: drives cell proliferation and cell cycle progression, supporting vascular sprouting and expansion
· PLCγ–PKC pathway: regulates calcium signaling and vascular permeability
· Src/FAK pathway: controls cytoskeletal remodeling and cell migration

The coordinated activation of these pathways ensures tightly regulated angiogenesis under normal conditions.

VEGF Signaling in Disease

Dysregulation of VEGF signaling disrupts vascular homeostasis:
· Overactivation promotes tumor growth, invasion, and metastasis
· Insufficient signaling leads to impaired wound healing and ischemic diseases

Aberrant VEGF signaling is implicated in multiple diseases, including:
· Atherosclerosis (ATH)
· Myocardial infarction (MI)
· Diabetic retinopathy (DR)
· Age-related macular degeneration (AMD)

These disease contexts highlight the therapeutic potential of targeting the VEGF pathway.

Therapeutic Targeting of VEGF Pathway

Targeting VEGF signaling has become a cornerstone in oncology and ophthalmology:
l Ligand neutralization:
·Bevacizumab (anti-VEGF-A monoclonal antibody)
·Ranibizumab and Aflibercept (VEGF-Trap) for AMD and DR
l Receptor inhibition:
·Ramucirumab (anti-VEGFR-2 antibody)
·Multi-target tyrosine kinase inhibitors (e.g., Sorafenib, Sunitinib)
l Emerging strategies:
·Bispecific drugs (e.g., Faricimab targeting VEGF and Ang-2)
·Combination therapies with immune checkpoint inhibitors
·PROTAC-based degradation and gene/siRNA therapies

These approaches improve drug delivery via vascular normalization and enhance synergy with chemotherapy and immunotherapy. Future trends focus on personalized therapy and multi-pathway targeting .

Gene knockout cell models provide powerful tools to investigate VEGF signaling mechanisms across diseases and accelerate drug discovery. EDITGENE offers a comprehensive portfolio of validated VEGF pathway knockout cell lines, supporting:
l Angiogenesis research
l Tumor biology studies
l Vascular and metabolic disease modeling

Both in-stock and custom gene knockout cell models are available to ensure experimental flexibility and reproducibility.

FAQ

I want to study the role of VEGF in specific cancers (such as glioblastoma), but this cell type is not listed?

We offer customized services. You can provide your target cell line, and we will handle the entire process for you, from gene editing to monoclonal validation. Simultaneously, you can conduct preliminary experiments using universal models in HEK293 or HeLa to validate your scientific hypotheses.

Can these cells be used for in vivo experiments?

Absolutely. Many clients have inoculated mice with our VEGFA-KO or VEGFR2-KO tumor cell lines to study the effects of gene deletion on tumorigenesis, angiogenesis, and metastasis in vivo.

I plan to conduct a high-throughput drug screening and need a large number of cells from the same batch. Can you meet this requirement?

References

1. Lee, C., Kim, M. J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025). Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives. Signal Transduction and Targeted Therapy, 10(1), Article 170. https://doi.org/10.1038/s41392-025-02249-0

2. Shah, F. H., Nam, Y. S., Bang, J. Y., Hwang, I. S., Kim, D. H., Ki, M., & Lee, H. W. (2025). Targeting vascular endothelial growth receptor-2 (VEGFR-2): Structural biology, functional insights, and therapeutic resistance. Archives of Pharmacal Research, 48(5), 404–425.https://doi.org/10.1007/s12272-025-01545-1

3. Li, H. S., & Huang, X. G. (2025). Advances in the molecular signaling mechanisms of VEGF/VEGFR2 in fundus neovascularization disease (Review). Experimental and Therapeutic Medicine, 30, 143. https://doi.org/10.3892/etm.2025.12893

4. Liu, Y., Li, Y., Wang, Y., Lin, C., Zhang, D., Chen, J., Ouyang, L., Wu, F., Zhang, J., & Chen, L. (2022). Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. Journal of Hematology & Oncology, 15(1), Article 89. https://doi.org/10.1186/s13045-022-01310-7